← FDA DRUG APPROVALS

FDA ANDA · ANDA077036

CITALOPRAM HYDROBROMIDE

Sponsor: EPIC PHARMA LLC

APPLICATION
ANDA077036
TYPE
ANDA
ORIGINAL APPROVAL
2004-10-28
LATEST ACTION
2024-11-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL

Approval history

2024-11-15Labeling · Supplement 8 · standardAP
2024-11-15Labeling · Supplement 7 · standardAP
2009-09-02Labeling · Supplement 6AP
2008-07-02Labeling · Supplement 5AP
2007-10-25Labeling · Supplement 4AP
2007-06-27Labeling · Supplement 3AP
2006-01-24Labeling · Supplement 2AP
2005-04-29Labeling · Supplement 1AP
2004-10-28Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →